JCR Pharmaceuticals Co., Ltd, a specialty pharma engaged in the research, development, manufacture, and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases, and Eisai Co., Ltd. have concluded a feasibility study agreement that examined the possibility of applying JCR’s proprietary blood-brain-barrier (BBB) penetration technology “J-Brain Cargo” to the discovery of new treatments.

Under the agreement, JCR and Eisai will perform collaborative research using the J-Brain Cargo technology and certain pharmaceutical candidate compounds of Eisai’s choice, aiming to create pharmaceutical products primarily for diseases of the central nervous system.

J-Brain Cargo enables delivery of target substances across the BBB through a certain receptor expressed on the surface of vascular endothelial cells. JCR says its studies showed that J-Brain Cargo combined with a target substance increased BBB penetration as much as 20 to 100 times higher compared with the target substance alone. The technology can be used with small or large molecules.

Source: Eisai